The Clinical Value of an Artificial Intelligence System Using Abbreviated Protocol of Breast MRI Facilitates Classification of Breast Lessions

Sponsor
Fudan University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05892380
Collaborator
Bayer (Industry)
800
1
25
32

Study Details

Study Description

Brief Summary

This study aims to use a combination of abbreviated protocol and artificial intelligence to automatically identify lesions and make diagnosis without decreasing the diagnostic accuracy of breast cancer, thus enhancing the comfort of patient examination, accelerating the flow of examination and reducing the load of clinical work.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Full sequence of MRI scan is:
    MR scan protocol:
    1. Magnetic fields and coils: Use MR scanners with high fields of 1.5 T and above with dedicated breast coils.

    2. Scanning position: prone position with bilateral breasts naturally draped over the center of the breast coil. The position should ensure that all breast tissue is located in the coil, the skin and breast are not folded, the bilateral breast is symmetrical, the nipple is perpendicular to the ground, and the midline of the sternum is located in the middle line of the coil.

    3. Scanning sequence and parameters: T1WI non-fat suppressed sequence, T2WI fat suppressed sequence, dynamic five-phase enhanced T1WI fat suppressed sequence, and diffusion weighted imaging (DWI); delayed sagittal T1W1 fat suppressed sequence.

    Imaging parameters: the thickness of the scanned layer should be ≤3 mm, the resolution within the layer should be <1.5 mm, and the single scan time should be <2 min.

    Enhancement scan: Gadobutrol used as the contrast agent, and the injection dose was 0.1 ml/kg, which was injected through the elbow vein at a rate of 2-3 mL/s using a pressure syringe, and 10-20 mL of saline was injected into the tube at the same rate after the contrast agent injection. The T1WI sequences before and after enhancement were preferably fat-suppressed and bilateral mammary glands were imaged simultaneously, and subtraction treatment was recommended. The recommended duration of delayed enhancement scan is 7 min, not less than 5 min.

    Abbreviated sequences : T1WI + dynamic enhanced T1 phase I + maximum density projection images generated by automatic reconstruction in three directions. No extra sequences are required.

    By adding artificial inteeligence, a diagnostic performance comparable with full sequences is expected.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    800 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Clinical Value of an Artificial Intelligence System Using Abbreviated Protocol of Breast MRI Facilitates Classification of Breast Lessions
    Anticipated Study Start Date :
    Jul 1, 2023
    Anticipated Primary Completion Date :
    May 1, 2025
    Anticipated Study Completion Date :
    Aug 1, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Comparison between the diagnostic performance of【AP breast MRI + AI】 vs. 【Radiologist】, using the pathological results as golden standard, [2 years]

      Comparison of AUC, sensitivity, specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) between【AP breast MRI + AI】 vs. 【Radiologist】, using the pathological results as golden standard,

    Secondary Outcome Measures

    1. Comparison of the scan time of abbreviated and full protocol [2 years]

      Comparison of the scan time of abbreviated and full protocol

    2. Comparison of the interpretation time of abbreviated and full protocol [2 years]

      Comparison of the interpretation time of abbreviated and full protocol. Although abbreviated saves scan time, the interpretation time may increase because the usage of AI.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    1. Patients with breast lesions detected by ultrasound and mammography that cannot be characterized

    2. Patients who were consecutively included in our hospital for breast MRI without treatment

    3. Underwent preoperative full-protocol breast MRI

    4. Pathological results are available, of which benign lesions can be determined by follow-up

    Exclusion Criteria:
    1. Poor MRI image quality

    2. Patients who have been received the biopsy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Fudan university Shanghai Cancer Center Shanghai Shanghai China 200032

    Sponsors and Collaborators

    • Fudan University
    • Bayer

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yajia Gu, MD, Director of Radiology, Fudan University
    ClinicalTrials.gov Identifier:
    NCT05892380
    Other Study ID Numbers:
    • AMRI01
    First Posted:
    Jun 7, 2023
    Last Update Posted:
    Jun 7, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Yajia Gu, MD, Director of Radiology, Fudan University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 7, 2023